U.S. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Market Research: Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait? [Yahoo! Finance]
Moderna, Inc. (NASDAQ: MRNA) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.
Moderna, Inc. (NASDAQ: MRNA) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $41.00 price target on the stock.
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an "underweight" rating on the stock.